Table 3 Efficacy and exploratory clinical outcomes for angiotensin-II versus placebo
Outcome | Placebo | Angiotensin-II | Absolute difference (CI95%) | Relative risk (CI95%) | p-value |
|---|---|---|---|---|---|
n = 47 | n = 34 | ||||
Hour-3 | |||||
Treatment (MAP) response | 17 (36.2%) | 22 (64.7%) | 28.5% (6.5% to 47.0%) | 1.79 (1.14 to 2.82) | p = 0.0112 |
Hour-48 | |||||
Alive and ventilator-free | 1 (2.1%) | 0 (0.0%) | − 2.1% (− 12.7% to 10.7%) | 0.98 (0.88 to 1.09) | p = 0.39 |
Alive and vasopressor-free | 3 (6.4%) | 7 (20.6%) | 14.2% (− 4.3% to 30.8%) | 1.18 (1.00 to 1.49) | p = 0.0551 |
Mortality | 14 (29.8%) | 7 (20.6%) | − 9.2% (− 30.7% to 9.8%) | 0.69 (0.31 to 1.47) | p = 0.35 |
Day-7 | |||||
Alive and ventilator-free | 5 (10.6%) | 7 (20.6%) | 10.0% (− 5.8% to 27.2%) | 1.94 (0.62 to 6.12) | p = 0.21 |
Alive and vasopressor-free | 18 (38.3%) | 17 (50.0%) | 11.7% (− 9.9% to 32.0%) | 1.44 (0.74 to 2.79) | p = 0.29 |
Mortality | 25 (53.2%) | 14 (41.2%) | − 12.0% (− 32.0% to 9.7%) | 0.70 (0.36 to 1.34) | p = 0.29 |
Day-28 | |||||
Mortality | 32 (68.1%) | 19 (55.9%) | − 12.2% (− 32.3% to 8.7%) | 0.71 (0.40 to 1.26) | p = 0.26 |
Discharged alive from the hospital | 8 (17.0%) | 7 (20.6%) | 3.6% (− 13.1% to 21.7%) | 1.22 (0.44 to 3.37) | p = 0.68 |